EXEL
VENTE TOTALE: 9 812 titres (~526 511,92 $ US)
- Insiders
- Beckerle Mary C
- Total bought
- —
- Total sold
- $526,512
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-14
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-01-02 | 2025-01-03 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | |
| Ebit Margin | 38.5% | 31.8% | 14.1% | 14.5% | 20.5% | |
| Ebitda Margin | 39.7% | 33.1% | 15.5% | 15.8% | 21.4% | |
| Operating Profit Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | |
| Pretax Profit Margin | 40.6% | 31.4% | 14.1% | 14.5% | 20.5% | |
| Continuous Operations Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Net Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Bottom Line Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Current Ratio | 3.558 | 3.635 | 3.343 | 4.991 | 5.435 | |
| Quick Ratio | 3.505 | 3.579 | 3.299 | 4.888 | 5.353 | |
| Solvency Ratio | 1.188 | 0.782 | 0.344 | 0.348 | 0.603 | |
| Cash Ratio | 1.189 | 0.538 | 0.667 | 1.545 | 1.917 | |
| Price To Earnings Ratio | 15.132 | 18.872 | 36.908 | 28.140 | 25.041 | |
| Price To Earnings Growth Ratio | 0.252 | 0.107 | 2.630 | -1.284 | 0.244 | |
| Forward Price To Earnings Growth Ratio | 0.252 | 0.107 | 2.630 | -1.284 | 0.244 | |
| Price To Earnings Diluted Ratio | 15.676 | 19.301 | 36.908 | 28.643 | 25.389 | |
| Price To Earnings Diluted Growth Ratio | 0.270 | 0.113 | 2.296 | -1.289 | 0.240 | |
| Price To Book Ratio | 5.476 | 4.390 | 3.371 | 2.073 | 2.604 | |
| Price To Sales Ratio | 5.101 | 4.543 | 4.170 | 3.201 | 4.011 | |
| Price To Free Cash Flow Ratio | 14.017 | 15.545 | 44.803 | 23.007 | 17.102 | |
| Price To Operating Cash Flow Ratio | 13.384 | 14.075 | 22.898 | 14.222 | 14.361 | |
| Debt To Assets Ratio | 0.061 | 0.065 | 0.065 | 0.062 | 0.020 | |
| Debt To Equity Ratio | 0.080 | 0.085 | 0.084 | 0.076 | 0.023 | |
| Debt To Capital Ratio | 0.074 | 0.078 | 0.077 | 0.071 | 0.023 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.316 | 1.313 | 1.300 | 1.234 | 1.183 | |
| Working Capital Turnover Ratio | 2.208 | 2.182 | 1.650 | 1.154 | 1.048 | |
| Operating Cash Flow Ratio | 2.180 | 1.734 | 0.845 | 1.118 | 1.187 | |
| Operating Cash Flow Sales Ratio | 0.381 | 0.323 | 0.182 | 0.225 | 0.279 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.955 | 0.905 | 0.511 | 0.618 | 0.840 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 5.110 | 3.668 | 1.755 | 1.907 | 7.817 | |
| Capital Expenditure Coverage Ratio | 22.147 | 10.576 | 2.045 | 2.619 | 6.241 | |
| Dividend Paid And Capex Coverage Ratio | 22.147 | 10.576 | 2.045 | 2.619 | 6.241 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 12.504 | 13.671 | 26.689 | 18.988 | 16.766 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 96.4% | ▼-0.1% | ▲0.1% |
| Ebit Margin | 38.5% | ▲6.7% | ▲14.6% |
| Ebitda Margin | 39.7% | ▲6.6% | ▲14.6% |
| Operating Profit Margin | 37.6% | ▲9.7% | ▲16.1% |
| Pretax Profit Margin | 40.6% | ▲9.1% | ▲16.3% |
| Continuous Operations Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Net Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Bottom Line Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Current Ratio | 3.558 | ▼-0.077 | ▼-0.634 |
| Quick Ratio | 3.505 | ▼-0.075 | ▼-0.620 |
| Solvency Ratio | 1.188 | ▲0.406 | ▲0.535 |
| Cash Ratio | 1.189 | ▲0.651 | ▲0.018 |
| Price To Earnings Ratio | 15.132 | ▼-3.740 | ▼-9.687 |
| Price To Earnings Growth Ratio | 0.252 | ▲0.145 | ▼-0.138 |
| Forward Price To Earnings Growth Ratio | 0.252 | ▲0.145 | ▼-0.138 |
| Price To Earnings Diluted Ratio | 15.676 | ▼-3.625 | ▼-9.507 |
| Price To Earnings Diluted Growth Ratio | 0.271 | ▲0.158 | ▼-0.056 |
| Price To Book Ratio | 5.476 | ▲1.086 | ▲1.893 |
| Price To Sales Ratio | 5.101 | ▲0.558 | ▲0.896 |
| Price To Free Cash Flow Ratio | 14.017 | ▼-1.528 | ▼-8.878 |
| Price To Operating Cash Flow Ratio | 13.384 | ▼-0.692 | ▼-2.404 |
| Debt To Assets Ratio | 0.061 | ▼-0.004 | ▲0.006 |
| Debt To Equity Ratio | 0.080 | ▼-0.005 | ▲0.010 |
| Debt To Capital Ratio | 0.074 | ▼-0.004 | ▲0.009 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.316 | ▲0.003 | ▲0.047 |
| Working Capital Turnover Ratio | 2.208 | ▲0.026 | ▲0.559 |
| Operating Cash Flow Ratio | 2.180 | ▲0.446 | ▲0.767 |
| Operating Cash Flow Sales Ratio | 0.381 | ▲0.058 | ▲0.103 |
| Free Cash Flow Operating Cash Flow Ratio | 0.955 | ▲0.049 | ▲0.189 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 5.110 | ▲1.442 | ▲1.059 |
| Capital Expenditure Coverage Ratio | 22.146 | ▲11.571 | ▲13.421 |
| Dividend Paid And Capex Coverage Ratio | 22.146 | ▲11.571 | ▲13.421 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 12.504 | ▼-1.167 | ▼-5.220 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.83B | $9.85B | $7.63B | $5.16B | $5.76B | |
| Enterprise value | $11.53B | $9.83B | $7.56B | $4.85B | $5.16B | |
| EV / Sales | 4.97x | 4.53x | 4.13x | 3.01x | 3.60x | |
| EV / Op. cash flow | 13.03x | 14.04x | 22.68x | 13.37x | 12.88x | |
| EV / Free cash flow | 13.65x | 15.50x | 44.37x | 21.62x | 15.33x | |
| EV / EBITDA | 12.50x | 13.67x | 26.69x | 18.99x | 16.77x | |
| Net debt / EBITDA | -0.34x | -0.04x | -0.26x | -1.22x | -1.94x | |
| Current ratio | 3.56x | 3.63x | 3.34x | 4.99x | 5.43x | |
| Income quality | 1.13x | 1.34x | 1.60x | 1.99x | 1.74x | |
| Graham number | $23 | $18 | $10 | $10 | $11 | |
| Graham net-net | $2 | $2 | $2 | $3 | $4 | |
| Tax burden | 83.1% | 76.5% | 80.7% | 77.8% | 78.6% | |
| Interest burden | 105.4% | 98.8% | 100.0% | 100.0% | 100.0% | |
| Working capital | $1.04B | $1.06B | $923.7M | $1.29B | $1.50B | |
| Invested capital | $1.54B | $1.49B | $1.46B | $1.70B | $1.66B | |
| Return on assets | 27.5% | 17.7% | 7.1% | 5.9% | 8.8% | |
| Operating ROA | 30.1% | 20.5% | 5.7% | 7.1% | 12.1% | |
| Return on tangible assets | 28.1% | 18.1% | 7.2% | 6.1% | 9.1% | |
| Return on equity | 36.2% | 23.2% | 9.2% | 7.3% | 10.5% | |
| Return on invested capital | 29.7% | 18.2% | 5.4% | 5.7% | 9.9% | |
| Return on capital employed | 35.8% | 23.8% | 6.7% | 7.3% | 12.6% | |
| Earnings yield | 6.6% | 5.3% | 2.7% | 3.5% | 4.0% | |
| Free cash flow yield | 7.1% | 6.4% | 2.2% | 4.3% | 5.8% | |
| Capex / Op. cash flow | 4.5% | 9.5% | 48.9% | 38.2% | 16.0% | |
| Capex / Depreciation | 137.4% | 229.8% | 633.7% | 663.3% | 471.2% | |
| Capex / Sales | 1.7% | 3.1% | 8.9% | 8.6% | 4.5% | |
| SG&A / Sales | 22.4% | 22.7% | 29.7% | 28.5% | 28.0% | |
| R&D / Sales | 35.6% | 42.0% | 57.0% | 55.4% | 48.3% | |
| Stock comp / Sales | 4.9% | 4.3% | 5.8% | 6.7% | 8.4% | |
| Intangibles / Total assets | 2.2% | 2.2% | 2.2% | 2.1% | 2.4% | |
| Days sales outstanding | 45d | 45d | 47d | 49d | 73d | |
| Days payables outstanding | 129d | 183d | 170d | 206d | 167d | |
| Operating cycle | 140d | 152d | 135d | 259d | 262d | |
| Cash conversion cycle | 11d | -31d | -35d | 53d | 95d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+20.1%EV / Sales ▲+9.6%EV / EBITDA ▼-8.5%EV / Op. cash flow ▼-1.004Earnings yield ▲+0.013Graham number ▲+5.027
Profitability
Return on equity ▲+0.130Return on assets ▲+0.098Return on invested capital ▲+0.116Return on capital employed ▲+0.120Operating ROA ▲+0.096Income quality ▼-0.213Tax burden ▲+0.067
Efficiency
Days sales outstanding ▲+0.463Days payables outstanding ▼-53.713Operating cycle ▼-12.181Cash conversion cycle ▲+41.531Capex / Sales ▼-0.013R&D / Sales ▼-0.064
Balance-sheet strength
Current ratio ▼-0.077Net debt / EBITDA ▼-0.299Working capital ▼-26165000.000Invested capital ▲+55991000.000Intangibles / Total assets ▲+0.001
Change over 5 years
Valuation
Market cap ▲+105.6%EV / Sales ▲+38.1%EV / EBITDA ▼-25.4%EV / Op. cash flow ▲+0.159Earnings yield ▲+0.026Graham number ▲+11.950
Profitability
Return on equity ▲+0.258Return on assets ▲+0.187Return on invested capital ▲+0.199Return on capital employed ▲+0.232Operating ROA ▲+0.181Income quality ▼-0.605Tax burden ▲+0.046
Efficiency
Days sales outstanding ▼-27.495Days payables outstanding ▼-38.276Operating cycle ▼-122.717Cash conversion cycle ▼-84.441Capex / Sales ▼-0.028R&D / Sales ▼-0.128
Balance-sheet strength
Current ratio ▼-1.877Net debt / EBITDA ▲+1.600Working capital ▼-459512000.000Invested capital ▼-122278000.000Intangibles / Total assets ▼-0.002
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2024-01-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2019-06-04 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-04-16 | Donna Shalala | Sale (Partial) | $1,001 - $15,000 |
| 2019-02-06 | Donna Shalala | Purchase | $1,001 - $15,000 |
| 2019-01-09 | Donna Shalala | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-13 Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell
- 2026-08-12 EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL) NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The revenue shortfall came alon.
- 2026-08-11 EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders.
- 2026-08-10 Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL) On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell.
- 2026-08-08 Arkadios Wealth Advisors Purchases New Position in Exelixis, Inc. $EXEL Arkadios Wealth Advisors bought a new position in Exelixis, Inc. (NASDAQ: EXEL) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,098 shares of the biotechnology company''s stock, valued at approximately $476,000. Other hedge funds and other institutional investors have also bought and sold shares
- 2026-08-08 Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL Amundi cut its position in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,398 shares of the biotechnology company''s stock after selling 121,348 shares during the quarter. Amundi''s holdings in Exelixis were worth $1,475,000 at
- 2026-08-06 EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers ''26 View Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
- 2026-08-05 Exelixis Q2 Earnings Call Highlights Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program for the drug candidate.
- 2026-08-05 Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-05 Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript